Le Lézard
Classified in: Health, Science and technology
Subjects: NPT, TRI

Memorial Hermann and UTHealth conduct first sinus surgery in U.S. using augmented reality technology


HOUSTON, March 13, 2018 /PRNewswire-USNewswire/ -- Sinus surgeons with The University of Texas Health Science Center at Houston (UTHealth) and Memorial Hermann-Texas Medical Center are the first in the United States to use augmented reality technology during minimally invasive sinus procedures.

UTHealth sinus surgeons affiliated with Memorial Hermann-Texas Medical Center are the first in the U.S. to use augmented reality technology in minimally invasive sinus surgeries, allowing them to better navigate complex anatomy. (Photo courtesy M. Citardi)

"Augmented reality, which uses 3-D mapping and imagery, enhances our understanding of complex anatomy so surgical procedures are more precise," said Martin J. Citardi, M.D., chair of the Department of Otorhinolaryngology?Head and Neck Surgery in McGovern Medical School at UTHealth. "The addition of augmented reality to a surgical navigation serves as a GPS-like system and offers patients the benefits of minimally invasive surgery with lower risks and better outcomes." 

The initial uses of the technology included a March 2 case at Memorial Hermann-TMC in which Citardi performed revision image-guided functional endoscopic sinus surgery for recurrent chronic rhinosinusitis. In addition, the patient also had a fibro-osseous lesion blocking drainage from the left frontal sinus. 

"This was a complicated case. By using this technology, we were able to plan a pathway to drain that blocked frontal sinus and avoid the need for a more extensive procedure," Citardi said. 

Citardi believes augmented reality technology has the potential to improve many types of sinus procedures, including those performed for chronic rhinosinusitis, sinonasal polyps and even tumors.   

The surgery was performed using Stryker's Scopis Target Guided Surgery (TGS) technology, a system which gives surgeons the tools to plan pathways and critical structures in preoperative medical imaging scans. During surgery, this planning is overlaid onto the surgeon's endoscopic view of the surgical area. The system assists the surgeon in following the defined pathway and avoiding critical structures.

"This system also allows easy recording of both the surgery and surgical planning. Such digital content will be important for training of surgeons in the difficult area of endoscopic sinus surgery.  This will ultimately benefit patients," said Citardi, who is affiliated with UT Physicians, the clinical practice of McGovern Medical School, and Memorial Hermann-TMC.

CONTACT: Evan Koch, 713-704-5403, [email protected]

Memorial Hermann-Texas Medical Center is now offering lung transplants, establishing its reputation as an elite health center with a comprehensive transplant program covering all solid organs including kidney, liver and heart transplants.

SOURCE Memorial Hermann-Texas Medical Center


These press releases may also interest you

at 16:20
Pulse Biosciences, Inc. , a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablationtm (nsPFAtm) technology, today announced business updates and financial results for the fourth quarter and full year ended December 31,...

at 16:20
AN2 Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended...

at 16:20
Pulse Biosciences, Inc. , a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablationtm (nsPFAtm) technology, today announced that its Board of Directors has unanimously approved plans to initiate a rights offering. The...

at 16:19
Aflac Incorporated announced today that it will release first quarter 2024 financial results after the market closes on May 1, 2024. At that time, earnings materials, including the quarterly earnings release and financial supplement, will be...

at 16:15
Medpace Holdings, Inc. ("Medpace") today announced that it will report its first quarter 2024 financial results after the market close on Monday, April 22, 2024. The Company will host a conference call the following morning, Tuesday, April 23, 2024,...

at 16:15
  Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell...



News published on and distributed by: